DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy.
OBJECTIVE
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) measured the early vascular changes after administration of TRA-8, bevacizumab, or TRA-8 combined with bevacizumab in breast tumor xenografts.


METHODS
Groups 1-4 of nude mice bearing human breast carcinoma were injected with phosphate-buffered saline, TRA-8, bevacizumab, and TRA-8 + bevacizumab on day 0, respectively. DCE-MRI was performed on days 0, 1, 2, and 3, and thereafter tumors were collected for terminal deoxynucleotidyl transferase-mediated dUT nick end labeling and CD31 staining.


RESULTS
DCE-MRI measured a significant K (trans) change within 3 days after TRA-8 therapy that correlated with tumor growth arrest, which was not shown with statistical significance by histopathology at these early time points posttreatment. The K (trans) changes followed quadratic polynomial curves.


CONCLUSIONS
DCE-MRI detected significantly lower K (trans) levels in breast tumor xenografts following TRA-8 monotherapy or combined therapy with bevacizumab.
Kim
Hyunki
H
The Department of Radiology, University of Alabama at Birmingham, AL 35294, USA. Hyunki@uab.edu
Folks
Karri D
KD
Guo
Lingling
L
Stockard
Cecil R
CR
Fineberg
Naomi S
NS
Grizzle
William E
WE
George
James F
JF
Buchsbaum
Donald J
DJ
Morgan
Desiree E
DE
Zinn
Kurt R
KR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D051379:Mice; D008819:Mice, Nude; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000276:immunology*; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D000068258:Bevacizumab
J Biol Chem. 1998 Jun 5;273(23):14363-7
9603945
Nat Med. 2001 Aug;7(8):954-60
11479629
Neoplasia. 2000 Jan-Apr;2(1-2):152-65
10933074
Child Dev. 1985 Aug;56(4):787-809
4042744
Magn Reson Med. 2007 Aug;58(2):270-80
17654590
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Kidney Int. 2007 Aug;72(3):260-4
17507905
Nat Med. 2000 May;6(5):564-7
10802713
Magn Reson Imaging. 2005 May;23(4):519-29
15919597
J Clin Oncol. 2006 Feb 10;24(5):769-77
16391297
J Transl Med. 2005 May 19;3(1):22
15943879
J Magn Reson Imaging. 2004 Jan;19(1):68-75
14696222
Invest Radiol. 1992 Aug;27 Suppl 1:S12-5
1506147
Science. 1997 Aug 8;277(5327):818-21
9242611
J Ultrasound Med. 2007 Jun;26(6):749-56
17526606
J Clin Oncol. 2005 Aug 20;23(24):5464-73
16027440
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3731-41
14506165
Breast Cancer Res Treat. 2003 Mar;78(1):51-8
12611457
Mol Cancer Ther. 2007 Mar;6(3):866-75
17363481
Magn Reson Med. 2004 Mar;51(3):542-51
15004796
Radiology. 2008 Sep;248(3):844-51
18710978
Magn Reson Imaging. 2007 Apr;25(3):319-27
17371720
J Neurol Sci. 2007 Aug 15;259(1-2):53-60
17395209
Magn Reson Med. 2007 Feb;57(2):353-61
17260371
Radiology. 2002 May;223(2):319-25; discussion 326-7
11997531
Technol Cancer Res Treat. 2006 Aug;5(4):401-10
16866570
Cancer Lett. 2003 Nov 10;201(1):17-24
14580682
Cancer Biother Radiopharm. 2010 Feb;25(1):13-9
20187792
Neoplasia. 2004 May-Jun;6(3):213-23
15153333
Breast Cancer Res Treat. 2004 Jan;83(1):67-76
14997056
Eur J Cancer. 2004 Apr;40(6):802-20
15120036
Magn Reson Med. 2002 Jun;47(6):1110-20
12111957
J Magn Reson Imaging. 1999 Sep;10(3):223-32
10508281
Nihon Rinsho. 2007 Jun 28;65 Suppl 6:385-8
17679210